Clinical Utility and Diagnostic Accuracy of ROMA, RMI, ADNEX, HE4, and CA125 in the Prediction of Malignancy in Adnexal Masses
Cancers · 11.11.2024 · 16 (22) · 3790
DOI: 10.3390/cancers16223790 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 11.11.2024. Verfasst von Giulia Spagnol und 11 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35122 Padua, Italy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
We aimed to compare the clinical utility and diagnostic accuracy of the ADNEX model, ROMA score, RMI I, and RMI IV, as well as two serum markers (CA125 and HE4) in preoperative discrimination between benign and malignant adnexal masses (AMs).
Methods
We conducted a retrospective study extracting all consecutive patients with AMs seen at our Institution between January 2015 and December 2020. Accuracy metrics included sensitivity (SE), specificity (SP), and area under the receiver operating characteristic curve (AUC), and their 95% confidence intervals (CI) were calculated for basic discrimination between AMs. Model performance was evaluated in terms of discrimination ability and clinical utility (net benefit, NB).
Results
A total of 581 women were included; 481 (82.8%) had a benign ovarian tumor and 100 (17.2%) had a malignant tumor. The SE and SP of CA125, HE4, ROMA score, RMI I, RMI IV, and ADNEX model were 0.60 (0.54–0.66) and 0.80 (0.76–0.83); 0.39 (0.30–0.49) and 0.96 (0.94–0.98); 0.59 (0.50–0.68) and 0.92 (0.88–0.95); 0.56 (0.46–0.65) and 0.98 (0.96–0.99); 0.54 (0.44–0.63) and 0.96 (0.94–0.98); 0.82 (0.73–0.88) and 0.91 (0.89–0.94), respectively. The overall AUC was 0.76 (0.74–0.79) for CA125, 0.81 (0.78–0.83) for HE4, 0.82 (0.80–0.85) for ROMA, 0.86 (0.84–0.88) for RMI I, 0.83 (0.81–0.86) for RMI IV, and 0.92 (0.90–0.94) for ADNEX. The NB for ADNEX was higher than other biomarkers and models across all decision thresholds between 5% and 50%.
Conclusions
The ADNEX model showed a better discrimination ability and clinical utility when differentiating malignant from benign Ams, compared to CA125, HE4, ROMA score, RMI I, and RMI IV.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35122 Padua, Italy.
- Department of Diagnostics and Public Health, University of Verona, 37129 Verona, Italy.
- Department of Primary Care, ULSS 1 Dolomiti, 32100 Belluno, Italy.
- 1st Unit of Obstetrics and Gynecology, Department of Biomedical and Human Oncological Science (DIMO), University of Bari, Policlinico, 70121 Bari, Italy.
- Independent Statistician, 36020 Solagna, Italy.
ORCID-Profile: Matteo Marchetti, Massimo Carollo, Sofia Bigardi, Roberto Tozzi, Carlo Saccardi
Zitieren
APA
Spagnol, G., Marchetti, M., Carollo, M., Bigardi, S., Tripepi, M., Facchetti, E., De Tommasi, O., Vitagliano, A., Cavallin, F., Tozzi, R., Saccardi, C., & Noventa, M. (2024). Clinical Utility and Diagnostic Accuracy of ROMA, RMI, ADNEX, HE4, and CA125 in the Prediction of Malignancy in Adnexal Masses. Cancers, 16(22), 3790. https://doi.org/10.3390/cancers16223790
Vancouver
Spagnol G, Marchetti M, Carollo M, Bigardi S, Tripepi M, Facchetti E, et al. Clinical Utility and Diagnostic Accuracy of ROMA, RMI, ADNEX, HE4, and CA125 in the Prediction of Malignancy in Adnexal Masses. Cancers. 2024;16(22):3790. doi:10.3390/cancers16223790
BibTeX
@article{Spagnol2024,
author = {Spagnol, Giulia and Marchetti, Matteo and Carollo, Massimo and Bigardi, Sofia and Tripepi, Marta and Facchetti, Emma and De Tommasi, Orazio and Vitagliano, Amerigo and Cavallin, Francesco and Tozzi, Roberto and Saccardi, Carlo and Noventa, Marco},
title = {Clinical Utility and Diagnostic Accuracy of ROMA, RMI, ADNEX, HE4, and CA125 in the Prediction of Malignancy in Adnexal Masses},
journal = {Cancers},
year = {2024},
volume = {16},
number = {22},
pages = {3790},
doi = {10.3390/cancers16223790}
}
EUVIMED